Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Drop in Short Interest

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the target of a large drop in short interest during the month of September. As of September 30th, there was short interest totaling 12,868 shares, a drop of 42.7% from the September 15th total of 22,465 shares. Based on an average daily volume of 277,145 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.6% of the shares of the company are sold short.

Xenetic Biosciences Stock Performance

Shares of NASDAQ XBIO traded down $0.02 during trading hours on Friday, hitting $1.99. 17,528 shares of the stock were exchanged, compared to its average volume of 61,558. Xenetic Biosciences has a 1-year low of $1.87 and a 1-year high of $4.94. The company has a market cap of $4.56 million, a PE ratio of -1.72 and a beta of 2.19. The company’s fifty day simple moving average is $3.14 and its two-hundred day simple moving average is $3.04.

Xenetic Biosciences (NASDAQ:XBIO) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.41) EPS for the quarter. Xenetic Biosciences had a negative net margin of 75.90% and a negative return on equity of 40.62%. The company had revenue of $0.66 million during the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Thursday. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for oncology. The company’s research is centered on treatments for difficult-to-treat cancers, including hematologic malignancies.

Xenetic’s principal technology is XCART, a personalized chimeric antigen receptor T-cell therapy platform designed to create individualized treatments that target tumor-specific antigens on a patient’s cancer cells. The platform has been developed with an initial focus on B-cell malignancies, including multiple myeloma, where tumor heterogeneity can limit the effectiveness of conventional therapies.

The company’s activities primarily involve research, preclinical development and clinical advancement of its oncology pipeline through collaborations and strategic partnerships.